Thumbnail
Access Restriction
Authorized

Author Radhakrishnan, V. V. ♦ Sumi, M. G. ♦ Reuben, S. ♦ Mathai, A. ♦ Nair, M. D.
Source Sree Chitra Tirunal Institute for Medical Sciences & Technology
Content type Text
Publisher Acta Neurologica Scandinavica
File Format PDF
Language English
Subject Domain (in DDC) Technology ♦ Medicine & health ♦ Diseases
Subject Domain (in MeSH) Nervous System Diseases ♦ Diseases
Subject Keyword Neurology
Abstract Objectives - To estimate the serum concentrations of Tumour Necrosis Factor alpha (TNF-alpha) and soluble TNF receptors (s TNF-RI and TNF-RII) in patients with Guillain-Barre syndrome (GBS), before and after treatment. Material and methods - The serum TNF-alpha and the soluble TNF receptors concentrations were measured by a sandwich enzyme-linked immunosorbent assay (ELISA) in 47 patients with GBS before and after the treatment - IVI therapy (n = 26); Plasma Exchange (n = 21). Results- At the time of admission, the serum TNF-alpha concentrations were elevated (32.5-182.5 pg/ml) in 41/47 GBS patients (87.2%). Following the treatment (IVIG or PE), there was a significant decrease in the serum TNF-alpha concentrations (8.5-58.5 pg/ml) in these 41 GBS patients. The soluble TNF receptors, particularly sTNF-RII concentrations were significantly increased in GBS patients treated by IVIG therapy. Conclusions - The results of this indicated that (a) Elevated serum concentrations of TNF-alpha showed a positive correlation with the disease severity in patients with GBS. (b) The decrease in the serum TNF-alpha and increase in the serum soluble TNF receptors, particularly sTNF-RII showed a positive correlation with the neurological recovery in GBB patients following treatment.
Education Level UG and PG
Learning Resource Type Article
Educational Framework Medical Council of India (MCI)
Journal ACTA NEUROLOGICA SCANDINAVICA
Volume Number 109
Issue Number 1
Page Count 4
Starting Page 71
Ending Page 74